123599-78-0

Basic information

• Product Name: [(2-Methyl-1-propionylpropoxy)(4-phenylbutyl)phosphinoyl]acetic acid
• Synonyms: [(2-Methyl-1-propionylpropoxy)(4-phenylbutyl)phosphinoyl]acetic acid;[[2-Methyl-l-(l-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetic acid;[2-Methyl-l-(l-Oxopropoxy)Propoxy][(4-Phenylbutyl)Phosphinyl]Acetic Acid;Fosinopril intermediate;rac-Des(4-cyclohexyl-L-proline) Fosinopril Acetic Acid;rac-2-[[2-Methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetic Acid;rac-Des(4-cyclohexyl-L-proline) Fosinopril Acetic Acid (Mixture of Diastereomers);2-(((2-Methyl-4-oxohexan-3-yl)oxy)(4-phenylbutyl)phosphoryl)acetic acid
• CAS NO: 123599-78-0
• Molecular Formula: C19H29O6P
• Molecular Weight: 384.41
• EINECS: 1592732-453-0
• Product Categories: Aromatics;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 123599-78-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 519.841 °C at 760 mmHg
• Flash Point: 268.191 °C
• Appearance: Brown crystal
• Density: 1.154 g/cm³
• Vapor Pressure: 1.24E-11mmHg at 25°C
• Refractive Index: 1.503
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: [(2-Methyl-1-propionylpropoxy)(4-phenylbutyl)phosphinoyl]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [(2-Methyl-1-propionylpropoxy)(4-phenylbutyl)phosphinoyl]acetic acid(123599-78-0)
• EPA Substance Registry System: [(2-Methyl-1-propionylpropoxy)(4-phenylbutyl)phosphinoyl]acetic acid(123599-78-0)

Safety Data

• Hazardous Substances Data: 123599-78-0(Hazardous Substances Data)

Usage

Chemical Properties

White Low Melting Solid

Uses

Different sources of media describe the Uses of 123599-78-0 differently. You can refer to the following data:
1. Fosinopril (F727800) intermediate.
2. Fosinopril

InChI:InChI=1/C19H29O6P/c1-4-18(22)24-19(15(2)3)25-26(23,14-17(20)21)13-9-8-12-16-10-6-5-7-11-16/h5-7,10-11,15,19H,4,8-9,12-14H2,1-3H3,(H,20,21)

Upstream product

• 58304-65-7 propanoic acid,1-chloro-2-methylpropyl ester 
• 87460-09-1 [Hydroxy-(4-phenylbutyl)phosphinyl]acetic acid,phenylmethyl ester 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF

The present invention relates to a process for the preparation of intermediates useful in the synthesis of [1[S(R)],2α,4β]-4-cyclohexyl-1-[[[2-methyl-1-oxypropoxy)propoxy](4-phenylbutyl phosphinyl]acetyl]L-proline, and the synthesis thereof, in particular as sodium salt (fosinopril sodium).

Process for the preparation of fosinopril and intermediates thereof

Process for the preparation of intermediates useful in the synthesis of [1[S(R)],2α,4β]-4-cyclohexyl-1-[[[(2-methyl-1-oxypropoxy) propoxy](4-phenylbutyl) phosphinyl]acetyl]-L-proline, and the synthesis thereof, in particular as sodium salt.

Method for preparing phosphinic acids used in preparing ace inhibitors and intermediates produced thereby

A method is provided for preparing phosphinic acid compounds, which are useful in preparing certain angiotensin converting enzyme inhibitors, which have the formula STR1 wherein R 1 is lower alkyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl;R 2 is hydrogen, lower alkyl or arylalkyl;X is hydrogen, lower alkyl or phenyl;Y is hydrogen, lower alkyl, phenyl or alkoxy, or together X and Y are --(CH 2) 2 --, --(CH 2) 3 --, --CH CH--, or STR2 and n is 0 or 1including salts thereof and stereoisomers thereof, which method includes the steps of reacting a phosphinic acid ester of the structure STR3 wherein R 3 is a group removable by hydrogenolysis such as benzyl or substituted benzyl, with a halo ester of the structure STR4 in the presence of an organic base to form a phosphinic acid ester of the structure STR5 hydrogenating the above ester to form a diastereomic mixture of a phosphinic acid of the structure STR6 recrystallizing to recover the preferred racemic mixture and resolving same employing a resolving agent, preferably L-cinchonidine, to form the corresponding resolved salt which may be acidified to the corresponding acid. In addition, novel intermediates which are acids and salts as described above are also provided.